To include your compound in the COVID-19 Resource Center, submit it here.

Kura reports Phase II data for tipifarnib in CMML

Kura Oncology Inc. (NASDAQ:KURA) reported preliminary data from nine evaluable patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE